domenica 15 gennaio 2017

I dati del DPA, sarebbe giusto fare chiarezza

E' uscita la relazione del DPA che mette in mostra i dati relativi al mercato della cannabis. Stimano un mercato che vale 4 miliardi di euro. Il dato, che è una stima, perchè non si basa su dei consumi effettivamente registrati, e probabilmente poco o per nulla attendibile.

Nella presentazione portata alla commissione giustizia nel 2013, L' economia della sicurezza pubblica, sulla basa dei dati riscontrabili nella "Relazione Europea sulla droga" 2013 e il report "EU Drug markets Report" emergono numeri diversi.

L' Italia era primo consumatore europeo di hashish con una quota pari al 30% di un mercato stimato in 1300 tonnellate e il terzo mercato per infiorescenze di cannabis ( 1200 tonnellate consumate annualmente in europa). Sulla base di questi dati emerge un fatturato annuo, del mercato italiano della cannabis di circa 5.6 miliardi di euro.

Quindi la domanda è: se i dati del 2013 europei parlano di un mercato di quasi 6 miliardi di euro solo per la cannabis e i derivati, da dove arrivano i numeri del DPA di oggi? Se i dati sono stati presi dall' ISTAT c'è un errore del circa 50% sulle stime (se si considera di passare da 4 miliardi a 6).

In Europa, i dati sulle statistiche delle droghe, non sono ritenuti più attendibili da anni; sulla base di cosa si continuano a tirare fuori numeri dal cilindro?

giovedì 12 gennaio 2017

Senate Banking Committee Could Pave the Way to a Bankable Marijuana Industry

NEW YORK, January 11, 2017 /PRNewswire/ -- News Coverage: Last month, a letter signed by 10 U.S. senators arrived on the desk of Jamal El-Hindi, the acting director of the Financial Crimes Enforcement Network (FINCEN), requesting guidance on how banking services might be offered to "indirect businesses" - such as SinglePoint, Inc. (OTC: SING), Medical Marijuana, Inc. (OTC: MJNA) and Cannabis Science, Inc. (OTC: CBIS) - that serve the state-sanctioned marijuana industry. The implications of such guidance also carry considerable potential for banking players ranging from small financial institutions to bellwether banks like Bank of America (NYSE: BAC) and Citigroup (NYSE: C).

The letter came at the prompting of U.S. Senator Elizabeth Warren, D-Mass, a member of the Senate Banking Committee that oversees federal monetary policy, banking regulation and issues affecting the U.S. currency. It's a widely applauded push, and SinglePoint, Inc. for one, is banking on this initiative to clear the way for payment processing providers, such as its SingleSeed Payments subsidiary, to offer an array of payment and transaction services to marijuana shops and dispensaries.

According to a recent report in the Houston Chronicle (, this action is part of a wider effort by many policymakers to regularize the patchwork legal nature of the $7 billion marijuana industry, marked by a lack of banking options that forces marijuana businesses "to rely solely on cash, making them tempting targets for criminals."

Although 28 states and the District of Columbia have now legalized either adult recreational or medical use of marijuana, the Drug Enforcement Administration (DEA) still classifies it as a Schedule I substance "with no currently accepted medical use and a high potential for abuse." Yet, there is growing evidence in the medical profession and the general population that marijuana has beneficent therapeutic properties.

Companies like Cannabis Science, Inc. (OTC: CBIS) have set out to develop novel cannabinoid-based therapies for unmet medical needs, while others like Medical Marijuana, Inc. (OTC: MJNA) - the first publicly traded cannabis company - focuses on a variety of cannabinoid-based applications for consumer and medical markets.

In a collection of 60 peer-reviewed studies on medical marijuana ( examining the employment of marijuana in the treatment of a long list of ailments - including amyotrophic lateral sclerosis (ALS), cancer and HIV/AIDS - 41 (68.3%) demonstrated positive results. Another 14 (23.3%) were inconclusive, and five (8.3%) of the trials reported negative outcomes.

Senator Warren has argued that loosening the restrictions that force marijuana business to transact in cash payments has a number of advantages.

"You make sure that people are really paying their taxes. You know that the money is not being diverted to some kind of criminal enterprise. And it's just a plain old safety issue. You don't want people walking in with guns and masks and saying, 'Give me all your cash.'"

There is some hope that the barriers preventing payment services providers like SingleSeed from doing business with marijuana establishments will be removed. FINCEN previously lent a sympathetic ear to similar pleas. In February 2014, the bureau offered guidance on how financial institutions could provide services to marijuana-related businesses consistent with their Bank Secrecy Act obligations.

That earlier guidance appears to have been tailored to businesses that dealt directly in marijuana like pot shops and marijuana dispensaries. It did not address the plight of the indirect businesses that service the marijuana industry, leaving it up to individual financial institutions to determine how to classify and treat indirect businesses.

Tossing the buck to financial institutions has had paltry success: "the number of banks and credit unions willing to handle pot money rose from 51 in 2014 to 301 in 2016," a figure that appears encouraging until placed in a wider context. There are 11,954 federally regulated banks and credit unions. In general, it's still an area dominated by small state-chartered banks and credit unions. Supporters of a bankable marijuana industry, however, see an inevitable day when large banks like Bank of America and Citigroup will offer full banking services to the cannabis industry.

When that day comes, financial technology (fintech) companies will have the chance to capitalize on a monstrous opportunity. SinglePoint's SingleSeed Payments subsidiary, for example, is already primed to offer ATM, Pay-by-Text[TM] and text message marketing to the cannabis industry. As it stands, progressive fintechs are in a similar quandary to their federally regulated counterparts and look forward to further guidance from FINCEN.

For more information, visit Singlepoint, Inc. (SING)

For more information about NetworkNewsWire, please visit
Please see full disclaimers on the NetworkNewsWire website:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

DISCLAIMER: is source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with NetworkNewsWire (NNW) or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. The companies that are discussed herein may or may not have approved the statements made in this release. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW & FNM undertakes no obligation to update such statements.

Media Contact e-mail: U.S. Phone: (954)345-0611


Senate Banking Committee Could Pave the Way to a Bankable Marijuana Industry

lunedì 9 gennaio 2017

Medical Marijuana Inc (OTCMKTS:MJNA) Is Building A Medical Marijuana Empire South Of The Border

By Chris Sandburg / in Momentum & Growth, Momentum Stocks, Sector Watch, Stocks / on Thursday, 29 Dec 2016 10:10 PM

Medical Marijuana Inc (OTCMKTS:MJNA) continues to climb higher into the close of 2016, as the company continues to push out updates relating to its operations. The company ran up into the November ballot along with the rest of the industry, but dipped into the latter part of the month, as traders took profits off the table. In our last coverage of this one, early December, we concluded that the company had plenty of upside potential left, and that it looked like a nice near to medium term momentum play on the back of this assumption.

We pointed out that the then-recent filing of an IP application by a a company in which Medical Marijuana holds a circa 35% position, Axim Biotechnologies Inc (OTCMKTS:AXIM), moved the latter, but failed to really move the latter, and that this was a bit of a red flag. Not enough to put us off completely, but enough to temper enthusiasm.

Anyway, that was then, this is now. What’s happened over the last few weeks, and what does it mean?

The company has focused on expansion in the central and south American markets, and it’s from this expansion that much of the value-add seen over the last few weeks derives. First up, Medical Marijuana announced that the cannabis regulations had been relaxed in Mexico, and that it was looking to build on its operations in the nation by expanding its full range into the Mexican market. The current product it sells into the space is a product called Real Scientific Hemp Oil-X, and it was the first-ever federally approved CBD product in Mexico. It’s got a portfolio of alternative Real Scientific products waiting in line to get in the country, and now the regulations have eased, the company should be able to start generating multiples of its Mexican revenues near term.

The next major update detailed the expansion of HempMeds (which is the subsidiary that sells the above mentioned product into the Mexican market) into Chile and Argentina. Shortly after that, we got word that the same product had started being sold in Brazil, so that gives HempMeds, and by proxy, Medical Marijuana, a solid presence south of the US border.

For us, these are all great moves, but we’re looking to the US as the market that’s going to drive real value, and as yet, things aren’t moving overly fast. So, that’s what we’re looking for next. Of course, the market is a little less mature in many of the US markets, but in places like California, we feel there is plenty of room for fast expansion. As such, we’re keeping an eye on releases purporting to these above-the-border markets before confirming a long term bias.

With that said, to build a medical marijuana operation in places like Mexico and Brazil is not an easy task, and that Medical Marijuana is making considerable inroads towards this task strengthens a near term these, given its current market capitalization. Weighing the company up against some of its peers in the space, Medical Marijuana has some real positives. It’s generating revenues, it’s got an international distribution network in place, and it’s got a great product in a rapidly growing, yet still very much nascent, industry.

Cash isn’t great, so we expect some degree of dilution if the company is to capitalize on its potential, but so long as management can put together a raise structure that isn’t overtly toxic to shareholders, there’s a definite momentum opportunity on this one.

Look to the continued stream of business development updates from South America to support near term value, and updates relating to the US operations as indicative of longer term potential.

mercoledì 4 gennaio 2017

Six Predictions For The Marijuana Industry In 2017

I write about retail and cannabis.  
This year saw big election wins for marijuana in several states. In addition, Colorado crossed the $1 billion mark for annual marijuana sales. Now a new year is almost here and a new presidential administration for the cannabis industry to navigate. It's time to look ahead and see what's in store for the cannabis industry in 2017.
The two biggest areas of focus for the upcoming year are California and Jeff Sessions. With California's recreational marijuana market in the building phase, many in the industry will be watching for progress throughout the year. Another big center of attention will be the appointment of Jeff Sessions as U.S. Attorney General. This will keep the industry on heightened alert for any changes in law enforcement.  Aside from those two topics, here are some of the industry’s biggest predictions for the 2017.
  1. Los Angeles Will Become The Marijuana Capital
Move over Denver, Adam Bierman Chief Executive Officer of cannabis investment firm MedMen Capital believes that the City of Angels will steal the spotlight from the Mile High City. Bierman said that by some estimates, Los Angeles's medical marijuana market alone is already close to $1 billion, easily overshadowing Colorado’s entire market. The city is expected to pass an ordinance in 2017 that will clear the path for a proper licensing program and open up the recreational market. Bierman said that capital is flowing into the area for local ventures as investors begin to smell money in the emerging market.
  1. A Sports League Will Green Light Marijuana
Bierman believes that in 2017 a major sports league will approve the use of cannabis for medical purposes. Many professional athletes have turned to using cannabis to treat pain and head injuries and are rejecting prescribed opiates. With medical marijuana legal in 29 states, the players are pushing to be treated just like other patients.
  1. A Primetime Network Show With A Marijuana Theme
With many polls showing that most Americans approve of legalizing marijuana, it won't be long before a major network will use marijuana as a backdrop. It's been over a decade since Showtime had a hit with Weeds. That series focused on a suburban mom that sold pot to make ends meet. It was considered ground breaking at the time with its taboo topic. Now HBO has High Maintenance and MTV's got Mary + Jane. Adam Scott from Parks and Recreation got a green light from NBC to develop a show called Buds about a dispensary in Denver. There isn't any timeline yet as to when the comedy could hit the air waves.
  1. An Increase In Interest For Synthetic CBD
With the Hemp Industries Association and the DEA battling over the legality of cannabis extracts like cannabinoids or CBD, there is an expectation for increased interest in synthetic cannabinoids. Seth Yakatan, the chief executive officer of biotech company Kalytera, said, “With AG Sessions and the DEA's clarification that plant derived CBD isn't legal federally, there will likely be interest in synthetic forms of CBD, which is what Kalytera has been testing the efficacy of for a few years.” Aside from the debate over whether CBD is legal or not, Yakatan is right that synthetic products do not have the legal limitations of other products. However, the synthetic products are not believed to be as effective as the natural products according to some patients. Fear over legal issues could create more demand for the synthetics.
  1. The Growth of Craft Marijuana
Sasha Kadey, Chief Marketing Officer of vaporizer distributor Greenlane, said he expects that as market supplies grow, prices will fall, causing a commoditizing effect. “This is leading to premiumization," he said. "Much like the alcohol industry experienced during its maturation, with producers now seeking to differentiate with premium packaging, brand building, so called “seed to sale” storytelling, and other value adds.” Other growers will stress their organic features, while some will push celebrity endorsements. It will be the year of the craft bud.
6. Recycling Marijuana Failures
The Cannabis Business Alliance is hoping to work with lawmakers to create options for marijuana that fails pesticide testing. Currently marijuana producers have to destroy crops that fail testing. The CBA is working towards a new rule to allow for these harvests to be turned into solvent-based concentrates that would be considered safe.

lunedì 26 dicembre 2016

Cannabis Science orders multiple greenhouse structures for its 2nd pilot 33,000 sq. ft. drug development facility buildout in Douglas County, Nevada.

Cannabis Science, Inc., a U.S. company specializing in the development of cannabinoid-based medications, has started work on its second 33,000 sq. ft. pilot cannabinoid drug development and manufacturing facility in Douglas County, Nevada.
"We have every intention of making 2017 the breakout year for our great company," said CEO Raymond C. Dabney. "To fast track our second pilot greenhouse and property build program, we ordered prefabricated and regular greenhouses. This second pilot property will house some of our grow operations and research and development activity.
"Our target is to begin growing a variety of prime strains in the first quarter of 2017. We need all the drug development capacity we can get, because we intend to ramp up our operations to meet the increased demand for cannabinoid medications across the country. This market is coming into full-bloom, and 2017 is the year we will be positioned to capitalize on this tremendous opportunity."
The Douglas County, Nevada multi-phased project is the second pilot site and is currently in full buildout of greenhouses, water-well development, extraction points, and manufacturing. The grow operations at this site will support the extraction of cannabinoids for the development of key proprietary formulations. The site management team is in place, and the labor crew is being hired locally to create jobs and economic benefits to the community. This multi-phased facility is officially under construction.
"The first quarter of 2017 will be an exciting time for more new product releases and much larger distribution channels. We will utilize various medication delivery methods (such as pills, creams, extracts, inhalers, tinctures, and balms) based on the ailment and we will release our cannabinoid-based medications across the country. I can't emphasis enough what an exciting and busy year 2017 looks to be," Dabney stated.
Cannabis Science is mapping out strategic demographic analyses across the country for full circle operations in each area: Grow, Lab Extraction, Manufacturing and Dispensaries. Having R&D and full circle operations and facilities in one site will allow Cannabis Science to bring its product to market more rapidly than before, while trimming costs for acquisition, extraction, and medication manufacturing.
While the company will place high emphasis on producing its existing product lines to meet the demand of current distributors, Cannabis Science will continue and expand the work on developing new product lines, which will allow them to access new patients across the country.
With over 3,500 acres in its portfolio in California and Nevada and much more under negotiations for future drug development projects, the company has a unique opportunity to scale out this model very quickly across the Western United States. Once this pilot buildout project in Nevada is complete and functional, the company will work on expanding its operations across the country.
(Source: Marketwired)

martedì 13 dicembre 2016

Cannabis Science Inc (OTCMKTS:CBIS) Takes A Step Forward

By Steven Goodstein / in Marijuana, Medical / on Tuesday, 13 Dec 2016 12:12 AM

Dr. Wilfred F. Ngwa, the Harvard Director of Global Health Catalyst at the DF/HCC, stated that Cannabis Science Inc (OTCMKTS:CBIS) presentation was a huge success. This development will lead to beneficial partnership opportunities between the firm and Harvard Medical School.
The expert view

Dr. Ngwa said that they were pleasantly surprised with the clearly targeted missions, direct plan of action and knowledge depth offered by Cannabis Science. They discussed the drug development success and advancement the company had made so far. Partnerships between renowned scientists and CBIS team at the DF/HCC are anticipated to bring in-depth knowledge of the potential effectiveness of cannabinoids in the cancer treatment and also other chronic diseases. Dr. Ngwa added that they will outline the motivations for research partnership with a viewpoint of successfully publishing details in a renowned peer-reviewed medical journal.

Mr. Dabney participated in the talks, and together with Melvin F. Foote and Dr. Allen A. Herman, the CMO of Cannabis Science delivered a comprehensive overview of the firm and its “Cannabis Science Research” Foundation. It covered details on cannabinoids treatment, targeting different critical ailments and validating the ability to destroy cancer cells and improve the therapeutic management of different types of cancers. It engaged the Harvard faculty members in deliberating approaches to establishing a research and drug development alliance between Dana Farber/Harvard Cancer Center and Cannabis Science.

Dr. Herman commented that during the roundtable talks, they received an opportunity to discuss prospective pre-clinical, and clinical research plans and objectives with the DF/HCC scientists. The drug advancement targeting will be implemented by the new association and is projected to alter the dynamics of phyto-pharmaceutical progression, particularly in the segments of clinical study design and program implementations.

Raymond C. Dabney, the CEO and President of Cannabis Science, said that with the support of renowned team of scientists of a prestigious cancer research institution, the company hopes to launch new therapies from research to FDA nod much more quickly. The partnership strength is underscored by an in-depth knowledge of the acceptance procedures at the Food and Drug Administration.

mercoledì 7 dicembre 2016

Piuttosto che legalizzare la cannabis ... fanno saltare il Governo

Ok. E' caduto il governo. Perchè? Perchè non vogliono legalizzare la cannabis.

Guardiamo i dati. La povertà alla quale questa classe politica ci ha portato, è frutto del loro arricchimento. Che si è fondato, tra le tante balle, che la cannabis non va legalizzata.

Ormai neppure più tutti i berlusconiani sono contro la legalizzazione. E' facile trovare in giornali di destra, titoli a favore della cannabis, sostenuti da idee economiche come quella portata da alcuni premi nobel dell'economia. Esistono ancora dei sostenitori del libero mercato e della libertà individuale. Insomma, non sono tutti fascisti a destra.

Ma torniamo alle dimissioni del premier. Questo governo, che da circa due anni ha incarico la richiesta di autorizzazione alla coltivazione alla cannabis, non si è ancora espresso.
Da un punto di vista economico quanto può avere danneggiato l' Italia?
Ebbene, circa il 20% del pil

Dopo «un quindicennio perduto», il Paese «soffre oggi di una debolezza superiore all’atteso» sottolineano da Viale dell’Astronomia ricordando come il contesto «resta molto difficile» con «tutti gli indicatori qualitativi al ribasso».

Ancora il sole24ore

Confindustria: Italia ferma 15 anni, altri crescono

«Non riusciamo a schiodarci dalla malattia della bassa crescita di cui soffriamo dall’inizio degli anni Duemila» avverte il capo economista di Confindustria, Luca Paolazzi. I dati Csc mostrano come «prima, durante e dopo la Grande Recessione (in Italia più intensa e più lunga) si è accumulato un distacco molto ampio» con altri Paesi Ue. Tra 2000 e 2015, ricorda Confindustria, il Pil è aumentato in Spagna del 23,5%, Francia +18,5%, Germania +18,2%. In Italia è «calato dello 0,5%» e con le dinamiche in corso i gap aumentano oggi «ancor più rapidamente».

Dall'Istat: I NUOVI CONTI NAZIONALI IN SEC 2010  Innovazioni e ricostruzione delle serie storiche (1995-2013),  “Le modifiche connesse al superamento delle riserve europee sull’implementazione del Sec 95 hanno contribuito alla revisione per 0,8 punti percentuali. Di queste, la modifica con il maggior impatto (1,0 punti percentuali) riguarda l’inclusione di alcune attività illegali tra l’economia non osservata.”
Scendendo nel dettagli di questa valutazione economica emergono alcuni dati interessanti elaborati dall’ufficio Statistico.
- “l’inclusione delle importazioni illegali di droga e tabacco di contrabbando ha inciso per 0,2 punti sulla revisione complessiva”
- “La spesa per consumi finali delle famiglie ha subito una revisione al rialzo del 4%, spiegata per 1,6 punti percentuali dalle riserve (quasi interamente connessa all’inclusione dell’economia illegale”

Avete mai sentito Renzi parlare di "riserve da parte dell'europa?"
Di 13 miliardi di flessibilità?Indovinate un pò di che flessibilità parla quando fa riferimento a quei numeri?Al mercato della cannabis!

Sempre nella nota informativa: "La componente più rilevante tra le tre attività illegali ora misurate dai conti nazionali riguarda la commercializzazione di droga, la quale, in termini di valore aggiunto, è valutata nel 2011 in 10,5 miliardi di euro.
Il valore aggiunto derivante da attività illegali è il risultato di una produzione valutabile in circa 16 miliardi a fronte della quale si stima un ammontare di costi intermedi pari a 1,7 miliardi; questi ultimi generano, a loro volta, un valore aggiunto di 1,2 miliardi connesso alla produzione di beni e servizi legali indotta da attività illegali (Prospetto 4). Pertanto, la stima delle attività illegali, comprensiva dell’indotto, comporta un’integrazione di valore aggiunto nei conti pari a 15,5 miliardi di euro, con un’incidenza sul nuovo livello del Pil pari, nel 2011 allo 0,9%. "

(Prospetto 4)
Se si confrontano i dati di confindustria, con le stime pil dell'Istat con le conseguenze delle scelte politiche sul tema cannabis, emerge un dato "drogato". Eh si. I dati italiani non sono attendibili. La politica italiana ha nascosto all'Europa, un business ,da 13 miliardi di euro l'anno, che avrebbe potuto portare l'italia a crescere al passo di Spagna, Germania e battere con orgoglio i cugini francesi.

L' uno per cento del pil che il mercato della cannabis ha sottratto ai dati ufficiali è allarmante e andrebbe messo in regola. Come? legalizzando la cannabis e dichiarando il mercato aperto e libero all'impresa.

Questa è una battaglia per lo sviluppo economico e la lotta alla povertà.

Istat, un residente su quattro in Italia è a rischio povertà o esclusione sociale: al Sud quasi il 50%

L' incidenza di 1,7 punti percentuali annui, per 15 anni, avrebbe reso l'italia più ricca, semplicemente facendo una somma aritmetica, di 25.5 punti percentuali di incidenza. Divenendo la locomotirice d'europa.

Ma la cannabis non è mai stata legale. E dunque oggi siamo poveri e (in)felici.

Ma queste argomentazioni potrebbero essere troppo tecniche. Perciò l' economia, per rendersi più accessibile, ha spiegato il pil come il reddito dello stato e, semplificando, la crescita del pil come la crescita del reddito del cittadino. Significa che 25.5 punti di pil persi, è il 25% perso nella crescita del  reddito medio di un cittadino italiano. L' italiano è in media più povero. ora si può dire per causa della repressione di un mercato illegale.

L' Italia con la cannabis legale? Lo stato più potente d'europa.